References:
1. Mion G. History of anaesthesia: The ketamine story - past, present and future. Eur J Anaesthesiol. 2017; 34(9):571–5.
2. Johnstone M, Evans V, Baigel S. Sernyl (CI-395) in clinical anaesthesia. Br J Anaesth. 1959 Oct; 31:433–9.
3. Domino EF, Chodoff P, Corssen G. PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN. Clin Pharmacol Ther. 1965 Jun; 6:279–91.
4. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983 Jun;79(2):565–75.
5. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013 Jun; 19(6):370–80.
6. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 1999 Oct 2; 843(1–2):171–83.
7. Sprenger T, Valet M, Woltmann R, Zimmer C, Freynhagen R, Kochs EF, et al. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth Analg. 2006 Sep;103(3):729–37.
8. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997 Apr; 86(4):903–17.
9. Sleigh J, Harvey M, Voss L, Denny B. Ketamine – More mechanisms of action than just NMDA blockade. Trends in Anaesthesia and Critical Care. 2014 Jun 1;4(2):76–81.
10. Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 2020 Feb;13(2):135–46.
11. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002; 7(8):837–44.
12. Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci. 2009 Jan 21; 29(3):600–9.
13. Schnoebel R, Wolff M, Peters SC, Bräu ME, Scholz A, Hempelmann G, et al. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents. Br J Pharmacol. 2005 Nov; 146(6):826–33.
14. Kinoshita H, Nishitani N, Nagai Y, Andoh C, Asaoka N, Kawai H, et al. Ketamine-Induced Prefrontal Serotonin Release Is Mediated by Cholinergic Neurons in the Pedunculopontine Tegmental Nucleus. Int J Neuropsychopharmacol. 2018 01; 21(3):305–10.
15. Larsen B, Hoff G, Wilhelm W, Buchinger H, Wanner GA, Bauer M. Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology. 1998 Nov; 89(5):1218–27.
16. Beilin B, Rusabrov Y, Shapira Y, Roytblat L, Greemberg L, Yardeni IZ, et al. Low-dose ketamine affects immune responses in humans during the early postoperative period. Br J Anaesth. 2007 Oct; 99(4):522–7.
17. Kawasaki C, Kawasaki T, Ogata M, Nandate K, Shigematsu A. Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anaesth. 2001 Sep; 48(8):819–23.
18. Yang J, Li W, Duan M, Zhou Z, Lin N, Wang Z, et al. Large dose ketamine inhibits lipopolysaccharide-induced acute lung injury in rats. Inflamm Res. 2005 Mar; 54(3):133–7.
19. Li CY, Chou TC, Wong CS, Ho ST, Wu CC, Yen MH, et al. Ketamine inhibits nitric oxide synthase in lipopolysaccharide-treated rat alveolar macrophages. Can J Anaesth. 1997 Sep; 44(9):989–95.
20. Dahmani S, Michelet D, Abback P-S, Wood C, Brasher C, Nivoche Y, et al. Ketamine for perioperative pain management in children: a meta-analysis of published studies. Paediatr Anaesth. 2011 Jun; 21(6):636–52.
21. Engelhard K, Werner C, Eberspächer E, Bachl M, Blobner M, Hildt E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S (+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003 Feb; 96(2):524–31, table of contents.
22. Proescholdt M, Heimann A, Kempski O. Neuroprotection of S(+) ketamine isomer in global forebrain ischemia. Brain Res. 2001 Jun 22; 904(2):245–51.
23. Carlton SM. Peripheral NMDA receptors revisited - Hope floats. Pain. 2009 Nov; 146(1–2):1–2.
24. Haeseler G, Tetzlaff D, Bufler J, Dengler R, Münte S, Hecker H, et al. Blockade of voltage-operated neuronal and skeletal muscle sodium channels by S(+)- and R(-)-ketamine. Anesth Analg. 2003 Apr; 96(4):1019–26, table of contents.
25. Wagner LE, Gingrich KJ, Kulli JC, Yang J. Ketamine blockade of voltage-gated sodium channels: evidence for a shared receptor site with local anesthetics. Anesthesiology. 2001 Dec; 95(6):1406–13.
26. Canbay O, Celebi N, Uzun S, Sahin A, Celiker V, Aypar U. Topical ketamine and morphine for post-tonsillectomy pain. Eur J Anaesthesiol. 2008 Apr; 25(4):287–92.
27. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A. 2010 Dec 17;1217(51):7942–8.
28. Rao LK, Flaker AM, Friedel CC, Kharasch ED. Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. Anesthesiology. 2016;125(6):1103–12.
29. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982 May; 71(5):539–42.
30. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010 Sep; 113(3):678–84.
31. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog. 1992; 39(3):61–8.
32. Pees C, Haas NA, Ewert P, Berger F, Lange PE. Comparison of analgesic/sedative effect of racemic ketamine and S (+)-ketamine during cardiac catheterization in newborns and children. Pediatr Cardiol. 2003 Oct; 24(5):424–9.
33. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain. 2010 Jul; 14(6):625–9.
34. Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 1995 May; 61(2):221–8.
35. Kuriyama A, Nakanishi M, Kamei J, Sun R, Ninomiya K, Hino M. Topical application of ketamine to prevent postoperative sore throat in adults: A systematic review and meta-analysis. Acta Anaesthesiol Scand. 2020; 64(5):579–91.
36. Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother. 2002; 16(3):27–35.
37. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996 Aug; 77(2):203–7.
38. Azevedo VM, Lauretti GR, Pereira NL, Reis MP. Transdermal ketamine as an adjuvant for postoperative analgesia after abdominal gynecological surgery using lidocaine epidural blockade. Anesth Analg. 2000 Dec; 91(6):1479–82.
39. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003 Jan; 24(1):37–43.
40. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018; 70(3):621–60.
41. Hornik CP, Gonzalez D, van den Anker J, Atz AM, Yogev R, Poindexter BB, et al. Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children. J Clin Pharmacol. 2018 Apr 20;
42. Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2014 Jun; 77(6):1011–6.
43. Bonanno FG. Ketamine in war/tropical surgery (a final tribute to the racemic mixture). Injury. 2002 May; 33(4):323–7.
44. Hudetz JA, Patterson KM, Iqbal Z, Gandhi SD, Byrne AJ, Hudetz AG, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2009 Oct; 23(5):651–7.
45. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014 Feb;77(2):357–67.
46. Marchetti F, Coutaux A, Bellanger A, Magneux C, Bourgeois P, Mion G. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. Eur J Pain. 2015 Aug; 19(7):984–93.
47. Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Am J Ther. 2006 Aug; 13(4):300–5.
48. Kamp J, Van Velzen M, Olofsen E, Boon M, Dahan A, Niesters M. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Expert Opin Drug Metab Toxicol. 2019 Dec; 15(12):1033–41.
49. Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZMN. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr. 2015 Dec 1; 15:198.
50. Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial. JAMA Pediatr. 2019 01; 173(2):140–6.
51. Lubega FA, DeSilva MS, Munube D, Nkwine R, Tumukunde J, Agaba PK, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018 26; 18(1):19–27.
52. Wong JJM, Lee JH, Turner DA, Rehder KJ. A review of the use of adjunctive therapies in severe acute asthma exacerbation in critically ill children. Expert Rev Respir Med. 2014 Aug;8(4):423–41.
53. Hendaus MA, Jomha FA, Alhammadi AH. Is ketamine a lifesaving agent in childhood acute severe asthma? Ther Clin Risk Manag. 2016; 12: 273–9.
54. Jat KR, Chawla D. Ketamine for management of acute exacerbations of asthma in children. Cochrane Database Syst Rev. 2012 Nov 14; 11:CD009293.
55. Fujikawa DG. Starting ketamine for neuroprotection earlier than its current use as an anesthetic/antiepileptic drug late in refractory status epilepticus. Epilepsia. 2019;60 (3):373–80.
56. Kim S, Rush BS, Rice TR. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Eur Child Adolesc Psychiatry. 2020 May 8;
57. Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013 Feb 12; 80(7):642–7.
58. Anghelescu DL, Tesney JM. Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. Paediatr Drugs. 2019 Apr; 21(2):59–70.
59. Taylor M, Jakacki R, May C, Howrie D, Maurer S. Ketamine PCA for treatment of end-of-life neuropathic pain in pediatrics. Am J Hosp Palliat Care. 2015 Dec; 32(8):841–8.
60. Courade M, Bertrand A, Guerrini-Rousseau L, Pagnier A, Levy D, Lervat C, et al. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. BMJ Support Palliat Care. 2019 May 31;
61. Conway M, White N, Jean CS, Zempsky WT, Steven K. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Oncol Nurs. 2009 Apr; 26(2):100–6.
62. Finkel JC, Pestieau SR, Quezado ZMN. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007 Jun; 8(6):515–21.
63. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006 Aug; 60(7):341–8.
64. Ramasubbu C, Gupta A. Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother. 2011; 25(3):219–30.
65. Michelet D, Hilly J, Skhiri A, Abdat R, Diallo T, Brasher C, et al. Opioid-Sparing Effect of Ketamine in Children: A Meta-Analysis and Trial Sequential Analysis of Published Studies. Paediatr Drugs. 2016 Dec; 18(6):421–33.
66. Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth. 1999 Dec; 11(8):663–8.
67. Bredlau A-L, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013 Jul; 163(1):194-200.e1.
68. World Health Organization. Persisting pain in children package: WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses [Internet]. World Health Organization; 2012 [cited 2020 Apr 20]. Available from: https://apps.who.int/iris/handle/10665/44540
69. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. [Internet]. 2018 [cited 2020 Jul 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537492/
70. Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol. 2001 Dec; 23(9):616–9.
71. Tsui BCH, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol. 2004 Oct; 26(10):678–80.
72. Ugur F, Gulcu N, Boyaci A. Oral ketamine for pain relief in a child with abdominal malignancy. Pain Med. 2009 Jan; 10(1):120–1.
73. Sheehy KA, Lippold C, Rice AL, Nobrega R, Finkel JC, Quezado ZM. Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: a single-center cohort study. J Pain Res. 2017; 10: 787–95.
74. Evans D, Turnham L, Barbour K, Kobe J, Wilson L, Vandebeek C, et al. Intravenous ketamine sedation for painful oncology procedures. Paediatr Anaesth. 2005 Feb; 15(2):131–8.
75. Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatr Emerg Care. 2009 May; 25(5):325–8.
76. Borker A, Ambulkar I, Gopal R, Advani SH. Safe and efficacious use of procedural sedation and analgesia by non-anesthesiologists in a pediatric hematology-oncology unit. Indian Pediatr. 2006 Apr; 43(4):309–14.
77. Chiaretti A, Ruggiero A, Barbi E, Pierri F, Maurizi P, Fantacci C, et al. Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists. Pediatr Blood Cancer. 2011 Dec 15; 57(7):1163–7.
78. McVey JD, Tobias JD. Dexmedetomidine and ketamine for sedation during spinal anesthesia in children. J Clin Anesth. 2010 Nov; 22(7):538–45.
79. Chayapathi V, Kalra M, Bakshi AS, Mahajan A. A comparison of ketamine + midazolam to propofol for procedural sedation for lumbar puncture in pediatric oncology by nonanesthesiologists-a randomized comparative trial. Pediatr Blood Cancer. 2018; 65(8):e27108.
80. Pellier I, Monrigal JP, Le Moine P, Rod B, Rialland X, Granry JC. Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. Paediatr Anaesth. 1999; 9(1):61–8.
81. Shi J, Li A, Wei Z, Liu Y, Xing C, Shi H, et al. Ketamine versus ketamine pluses atropine for pediatric sedation: A meta-analysis. Am J Emerg Med. 2018 Jul; 36(7):1280–6.
82. Bhatnagar S, Mishra S, Gupta M, Srikanti M, Mondol A, Diwedi A. Efficacy and safety of a mixture of ketamine, midazolam and atropine for procedural sedation in paediatric oncology: a randomised study of oral versus intramuscular route. J Paediatr Child Health. 2008 Apr; 44(4):201–4.
83. Rayala S, Kyander M, Haridass V, Palat G, Ström A, Wiebe T, et al. Low-dose Oral Ketamine as a Procedural Analgesia in Pediatric Cancer Patients Undergoing Bone Marrow Aspirations at a Resource-limited Cancer Hospital in India. Indian J Palliat Care. 2019 Dec; 25(4):501–7.
84. Shewale S, Saxena A, Trikha A, Singh M, Sharief A. Oral ketamine for radiotherapy in children with cancer. Indian J Pediatr. 2000 Apr; 67(4):263–6.
85. Yang F, Liu Y, Yu Q, Li S, Zhang J, Sun M, et al. Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine. Paediatr Anaesth. 2019; 29(1):85–91.
86. Marx CM, Stein J, Tyler MK, Nieder ML, Shurin SB, Blumer JL. Ketamine-midazolam versus meperidine-midazolam for painful procedures in pediatric oncology patients. J Clin Oncol. 1997 Jan; 15(1):94–102.
87. Heinz P, Geelhoed GC, Wee C, Pascoe EM. Is atropine needed with ketamine sedation? A prospective, randomised, double blind study. Emerg Med J. 2006 Mar; 23(3):206–9.
88. Monsereenusorn C, Rujkijyanont P, Traivaree C. The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial. J Med Assoc Thai. 2015 Apr; 98(4):358–64.
89. Abdolkarimi B, Zareifar S, Golestani Eraghi M, Saleh F. Comparison Effect of Intravenous Ketamine with Pethidine for Analgesia and Sedation during Bone Marrow Procedures in Oncologic Children: A Randomized, Double-Blinded, Crossover Trial. Int J Hematol Oncol Stem Cell Res. 2016 Oct 1; 10(4):206–11.
90. Rayala S, Bäckdahl T, Reddy N, Jacob J, Gebre-Medhin E, Karonen E, et al. Low-Dose Oral Ketamine for Procedural Analgesia in Pediatric Cancer Patients Undergoing Lumbar Puncture at a Resource-Limited Cancer Hospital in India. J Palliat Med. 2019; 22(11):1357–63.
91. Winegarden JA, Carr DB, Bradshaw YS. Topical Ketamine with Other Adjuvants: Underutilized for Refractory Cancer Pain? A Case Series and Suggested Revision of the World Health Organization Stepladder for Cancer Pain. J Palliat Med. 2020 Mar 11;
92. Hou S, Huh B, Kim HK, Kim K-H, Abdi S. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations. Pain Physician. 2018; 21(6):571–92.
93. Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014 Jul; 22(7):1807–14.
94. Tekelioglu UY, Apuhan T, Akkaya A, Demirhan A, Yildiz I, Simsek T, et al. Comparison of topical tramadol and ketamine in pain treatment after tonsillectomy. Paediatr Anaesth. 2013 Jun; 23(6):496–501.
95. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. Pain. 2009 Nov; 146(1–2):18–25.
96. Slatkin NE, Rhiner M. Topical ketamine in the treatment of mucositis pain. Pain Med. 2003 Sep; 4(3):298–303.
97. Ryan AJ, Lin F, Atayee RS. Ketamine mouthwash for mucositis pain. J Palliat Med. 2009 Nov; 12(11):989–91.
98. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017; 25(7):2215–9.
99. Prakash S, Meena JP, Gupta AK, Bakhshi S, Velpandian T, Pandey RM, et al. Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double-blind placebo-controlled trial. Pediatr Blood Cancer. 2020 Jul 10;e28573.
100. Keppel Hesselink JM, Kopsky DJ, Stahl SM. Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design. J Pain Res. 2017; 10:635–41.
101. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update. Annals of Emergency Medicine. 2011 May; 57(5):449–61.
102. Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med. 2013 Oct; 14(10):1505–17.
103. Hatab SZ, Singh A, Felner EI, Kamat P. Transient central diabetes insipidus induced by ketamine infusion. Ann Pharmacother. 2014 Dec; 48(12):1642–5.
104. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007 May; 69(5):810–2.
105. Chen W-Y, Huang M-C, Lin S-K. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy. 2014 Sep 22; 9:39.
106. Johnson PN, Miller JL, Hagemann TM. Sedation and analgesia in critically ill children. AACN Adv Crit Care. 2012 Dec; 23(4):415–34; quiz 435–6.
107. Youssef-Ahmed MZ, Silver P, Nimkoff L, Sagy M. Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm. Intensive Care Med. 1996 Sep;22(9):972–6.
108. Golding CL, Miller JL, Gessouroun MR, Johnson PN. Ketamine Continuous Infusions in Critically Ill Infants and Children. Ann Pharmacother. 2016 Mar; 50(3):234–41.
109. Ketamine. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006 [cited 2020 Jul 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK500566/
110. Evans J, Rosen M, Weeks RD, Wise C. Ketamine in neurosurgical procedures. Lancet. 1971 Jan 2; 1(7688):40–1.
111. Kaul HL, Jayalaxmi T, Gode GR, Mitra DK. Effect of ketamine on intracranial pressure in hydrocephalic children. Anaesthesia. 1976 Jun; 31(5):698–701.
112. Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. Neurocrit Care. 2014 Aug; 21(1):163–73.
113. Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg. 2005 Aug; 101(2):524–34, table of contents.
114. Bar-Joseph G, Guilburd Y, Tamir A, Guilburd JN. Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension. J Neurosurg Pediatr. 2009 Jul; 4(1):40–6.
115. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005 Dec; 162(12):2352–9.
116. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996 May; 14(5):301–7.
117. Paule MG, Li M, Allen RR, Liu F, Zou X, Hotchkiss C, et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol. 2011 Apr; 33(2):220–30.
118. Dong C, Rovnaghi CR, Anand KJS. Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells. Crit Care Med. 2012 Aug; 40(8):2407–16.
119. Soriano SG, Anand KJS, Rovnaghi CR, Hickey PR. Of mice and men: should we extrapolate rodent experimental data to the care of human neonates? Anesthesiology. 2005 Apr; 102(4):866–8; author reply 868-869.
120. Cheung HM, Yew DTW. Effects of Perinatal Exposure to Ketamine on the Developing Brain. Front Neurosci. 2019; 13:138.